These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

592 related articles for article (PubMed ID: 30415991)

  • 1. Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Ashley CW; Da Cruz Paula A; Kumar R; Mandelker D; Pei X; Riaz N; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2019 Jan; 152(1):11-19. PubMed ID: 30415991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Genetics of Endometrial Carcinoma.
    Bell DW; Ellenson LH
    Annu Rev Pathol; 2019 Jan; 14():339-367. PubMed ID: 30332563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
    Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of a custom designed next generation DNA sequencing gene panel to molecularly classify endometrial cancers according to The Cancer Genome Atlas subgroups.
    Miller EM; Patterson NE; Gressel GM; Karabakhtsian RG; Bejerano-Sagie M; Ravi N; Maslov A; Quispe-Tintaya W; Wang T; Lin J; Smith HO; Goldberg GL; Kuo DYS; Montagna C
    BMC Med Genomics; 2020 Nov; 13(1):179. PubMed ID: 33256706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.
    Rudd ML; Mohamed H; Price JC; O'Hara AJ; Le Gallo M; Urick ME; ; Cruz P; Zhang S; Hansen NF; Godwin AK; Sgroi DC; Wolfsberg TG; Mullikin JC; Merino MJ; Bell DW
    BMC Cancer; 2014 Nov; 14():884. PubMed ID: 25427824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and Genomic Analysis of
    Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
    Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
    Prendergast EN; Holman LL; Liu AY; Lai TS; Campos MP; Fahey JN; Wang X; Abdelaal N; Rao JY; Elvin JA; Moore KM; Konecny GE; Cohen JG
    Gynecol Oncol; 2019 Sep; 154(3):461-466. PubMed ID: 31257009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endometrial Cancers in
    Smith ES; Da Cruz Paula A; Cadoo KA; Abu-Rustum NR; Pei X; Brown DN; Ferrando L; Sebastiao APM; Riaz N; Robson ME; Soslow RA; Reis-Filho JS; Mandelker D; Weigelt B
    JCO Precis Oncol; 2019; 3():. PubMed ID: 32914019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of endometrial serous carcinoma reveals distinct clinicopathologic and genomic subgroups.
    Lin DI; Fine A; Danziger NA; Huang RSP; Mata DA; Decker B; Killian JK; Ramkissoon SH; Lechpammer M; Janovitz T; Ross JS; Sokol ES; Elvin JA
    Gynecol Oncol; 2022 Mar; 164(3):558-565. PubMed ID: 34998597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
    Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
    Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted gene sequencing of Lynch syndrome-related and sporadic endometrial carcinomas.
    Libera L; Craparotta I; Sahnane N; Chiaravalli AM; Mannarino L; Cerutti R; Riva C; Marchini S; Furlan D
    Hum Pathol; 2018 Nov; 81():235-244. PubMed ID: 30420047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCGA Classification of Endometrial Cancer: the Place of Carcinosarcoma.
    Travaglino A; Raffone A; Gencarelli A; Mollo A; Guida M; Insabato L; Santoro A; Zannoni GF; Zullo F
    Pathol Oncol Res; 2020 Oct; 26(4):2067-2073. PubMed ID: 32472441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
    Da Cruz Paula A; DeLair DF; Ferrando L; Fix DJ; Soslow RA; Park KJ; Chiang S; Reis-Filho JS; Zehir A; Donoghue MTA; Wu M; Brown DN; Murali R; Friedman CF; Zamarin D; Makker V; Mueller JJ; Leitao MM; Abu-Rustum NR; Aghajanian C; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):535-544. PubMed ID: 33622519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The genetic landscape of metaplastic breast cancers and uterine carcinosarcomas.
    Moukarzel LA; Ferrando L; Da Cruz Paula A; Brown DN; Geyer FC; Pareja F; Piscuoglio S; Papanastasiou AD; Fusco N; Marchiò C; Abu-Rustum NR; Murali R; Brogi E; Wen HY; Norton L; Soslow RA; Vincent-Salomon A; Reis-Filho JS; Weigelt B
    Mol Oncol; 2021 Apr; 15(4):1024-1039. PubMed ID: 33021035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterization of endometrial cancer and therapeutic implications.
    Uppendahl L; Mullany SA; Winterhoff B
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):35-39. PubMed ID: 27941362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; ; Merino MJ; Mutch DG; Goodfellow PJ; Mullikin JC; Bell DW
    Cancer; 2018 Jan; 124(1):65-73. PubMed ID: 28940304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated molecular profile of endometrioid ovarian cancer.
    Pierson WE; Peters PN; Chang MT; Chen LM; Quigley DA; Ashworth A; Chapman JS
    Gynecol Oncol; 2020 Apr; 157(1):55-61. PubMed ID: 32139151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.